NeuBase Therapeutics (NBSE)
(Delayed Data from NSDQ)
$0.38 USD
0.00 (0.00%)
Updated May 10, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for NeuBase Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 17 | 23 | 53 | 32 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 2 | 1 |
Total Current Assets | NA | 18 | 25 | 55 | 33 |
Net Property & Equipment | NA | 2 | 2 | 2 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 26 | 33 | 64 | 34 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 2 | 2 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 2 | 4 | 4 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 7 | 10 | 10 | 3 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 125 | 126 | 123 | 75 |
Retained Earnings | NA | -107 | -103 | -69 | -44 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 18 | 23 | 54 | 31 |
Total Liabilities & Shareholder's Equity | NA | 26 | 33 | 64 | 34 |
Total Common Equity | 0 | 18 | 23 | 54 | 31 |
Shares Outstanding | 3.70 | 1.60 | 1.60 | 1.10 | 0.80 |
Book Value Per Share | 0.00 | 11.39 | 14.49 | 49.15 | 39.11 |
Fiscal Year End for NeuBase Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | 13 |
Receivables | NA | NA | NA | NA | 0 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 0 |
Other Current Assets | NA | NA | NA | NA | 1 |
Total Current Assets | NA | NA | NA | NA | 13 |
Net Property & Equipment | NA | NA | NA | NA | 0 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | NA | NA | 0 |
Deposits & Other Assets | NA | NA | NA | NA | 0 |
Total Assets | NA | NA | NA | NA | 19 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | NA | NA | 0 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 0 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 0 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | NA | NA | 3 |
Total Current Liabilities | NA | NA | NA | NA | 5 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | NA | NA | NA | NA | 0 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | NA | NA | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | NA | NA | 9 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 0 |
Common Stock (Par) | NA | NA | NA | NA | 0 |
Capital Surplus | NA | NA | NA | NA | 126 |
Retained Earnings | NA | NA | NA | NA | -116 |
Other Equity | NA | NA | NA | NA | 0 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | NA | NA | 9 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 19 |
Total Common Equity | 0 | 0 | 0 | 0 | 9 |
Shares Outstanding | 3.70 | 3.70 | 3.70 | 3.70 | 3.70 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 2.47 |